EX-10.19



 Exhibit 10.19 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  
 



 
 Testing. Advising. Assuring. 

Analytical Testing Partnership Program 2014 - 2015 
  

			
	Quotation to:	  	 Intersect ENT
 1049 Elwell Court

Palo Alto CA 94303
 USA

		
	Attention:	  	 Rich Kaufman
 Chief Operating
Officer

		
	 Telephone:
 E-mail:
	  	 (650) 641 2107

rkaufman@intersectENT.com

		
	Quotation Number:	  	 13-011-00262 (Revision 7)
 6
Pages

		
	Date:	  	December 06, 2013










			
	 Analytical Testing Partnership Program 2014-2015
	  	Page 
2
 of 5
	For Intersect ENT	  	Quotation No.: 13-011-00262 (Revision 7)

  

 EXECUTIVE SUMMARY 

Exova’s Health Sciences group has developed a strong relationship with intersectENT during the past decade. Over this period services provided have
included method development, method and process validation, contaminant and unknown investigation, characterization of impurities, raw material and finished product testing and stability program services. 

lntersectENT has had major success in product development, clinical efficacy and approval of its novel stent products. The company is experiencing rapid
growth in moving from a purely research organization, to a manufacturing firm with a continuing R&D pipeline. 
 Exova has made investments to increase
our capacity in tandem, so that intersectENT can continue to rely on Exova as the vendor of choice for analytical support and development. We appreciate your regular feedback and this has been very valuable in making changes and improvements so that
our final product meets your expectations. 
 Exova is committed to working with intersectENT to manage costs during this period of rapid expansion, and to
arrive at a mutually beneficial and cost effective long term partnership. In this light, for the next 24 months Exova is pleased to offer reduced prices for [*] services. 

We are looking forward to continuing to support intersectENT for analytical testing development and stability needs. 

 

					
	 /s/ April Gamache
	 		 	 /s/ John McNeil

	 April Gamache, Chief Operating Officer,
 for
Eric Lindsay
	 		 	 John McNeil
 General Manager

	General Manager	 		 	Health Sciences Mississauga
	Health Sciences, Santa Fe Springs	 		 	


  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 










			
	 Analytical Testing Partnership Program 2014-2015
	  	Page 
3
 of 5
	For Intersect ENT	  	Quotation No.: 13-011-00262 (Revision 7)

  

 PRICING PROPOSAL 

Table 1. Custom Analyses 
  

					
	 Test Method
	  	 Price Structure

2014-2015

[*]
	  	 Price Structure

2014-2015

[*]

	 [*]
	  	[*]	  	[*]
	 [*]
	  	[*]	  	[*]
	 [*]
	  	[*]	  	[*]
	 [*]
	  	[*]	  	[*]
	 [*]
	  	[*]	  	[*]
	 [*]
	  	[*]	  	[*]
	 [*]
	  	[*]	  	[*]
	 [*]
	  	[*]	  	[*]
	 [*]
	  	[*]	  	[*]
	 [*]
	  	[*]	  	[*]
	 [*]
	  	[*]	  	[*]
	 [*]
	  	[*]	  	[*]
	 [*]
	  	[*]	  	[*]

  

	(1)	Raw Data packages are [*] of the total analytical cost, $[*] minimum and $[*] maximum. 


	(2)	The pricing indicated in the above table is quoted for [*] (please note; turnaround time is defined as delivery of the final C of A by 5PM on the day promised). 24 and 72 hour priority service will be accompanied by a
surcharge of [*] and [*], respectively. Exova’s pricing for intersectENT has not increased in five years, and with growing volumes in 2013 we are pleased to provide discounted pricing that passed along savings realized with volume efficiencies.



	(3)	To assist Exova in making compressed timing commitments, intersectENT will work to provide pre-notification whenever possible of upcoming sample submission schedules.



	(4)	Due to the lengthy nature of this procedure, to ensure that [*] turnaround commitments are consistently met, intersectENT will provide five to ten days forewarning of upcoming sample submissions and batch samples
shipments whenever possible. 


	(5)	Note: when [*] analysis is requested for [*], additional samples will be requested by Exova and the results available in less than five working days from sample receipt. 


	(6)	This test includes [*] as part of the listed fee (the data will be gathered/acquired [*]). No additional fee will be charged for [*]. 


  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 










			
	 Analytical Testing Partnership Program 2014-2015
	  	Page 
4
 of 5
	For Intersect ENT	  	Quotation No.: 13-011-00262 (Revision 7)

  

 Table 2. USP Monograph Testing 

 

			
	 Test Method
	  	 Price Structure

2014-2015

[*]

	 [*]
	  	
	 [*]
	  	[*]
	 [*]
	  	[*]
	 [*]
	  	[*]
	 [*]
	  	[*]
	 [*]
	  	[*]
	 [*]
	  	[*]
	 [*]
	  	[*]
	 [*]
	  	[*]
	 [*]
	  	[*]
		
	 [*]
	  	
	 [*]
	  	[*]
	 [*]
	  	[*]
	 [*]
	  	[*]
	 [*]
	  	[*]
	 [*]
	  	[*]
	 [*]
	  	[*]
	 [*]
	  	[*]
	 [*]
	  	[*]
	 [*]
	  	[*]
		
	 [*]
	  	
	 [*]
	  	[*]
	 [*]
	  	[*]
	 [*]
	  	[*]
	 [*]
	  	[*]
	 [*]
	  	[*]
	 [*]
	  	[*]
	 [*]
	  	[*]
		
	 [*]
	  	
	 [*]
	  	[*]
	 [*]
	  	[*]
	 [*]
	  	[*]
	 [*]
	  	[*]
	 [*]
	  	[*]
		
	 [*]
	  	
	 [*]
	  	[*]
	 [*]
	  	[*]
	 [*]
	  	[*]

  

	(1)	Raw Data packages are [*] of the total analytical cost, $[*] minimum and $[*] maximum. 


  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 










			
	 Analytical Testing Partnership Program 2014-2015
	  	Page 
5
 of 5
	For Intersect ENT	  	Quotation No.: 13-011-00262 (Revision 7)

  


	(2)	The pricing Indicated in the above table is quoted for [*] standard turnaround (please note: turnaround time is defined as delivery of the final C of A by SPM on the day promised). 24 and 72 hour priority service will
be accompanied by a surcharge of [*] and [*], respectively. Exova’s pricing for intersectENT has not increased in five years, and with growing volumes in 2013 we are pleased to provide discounted pricing that passed along savings realized with
volume efficiencies. 


	(3)	Pricing for [*] turnaround is offered at a [*]. To assist Exova in making compressed timing commitments, intersectENT will work to provide pre-notification whenever possible of upcoming sample submission schedules.



	(4)	To ensure that turnaround commitments are consistently met, intersectENT will provide five to ten days forewarning of upcoming sample submissions and batch samples shipments whenever possible. 


The pricing in the above tables is quoted for [*] day turnaround options. It is understood that [*]. 

TERMS AND CONDITIONS 
 This quotation is open for
acceptance until December 15, 2013, and these prices will be in effect until December 31, 2015. It can be accepted on or before this date by signing and returning to Exova. After the validity date, Exova reserves the right to revise and/or
withdraw the quotation as appropriate. This quotation has been prepared exclusively on behalf of Exova and is provided in confidence. The contents of this quotation including pricing Information is for the sole consideration of lntersectENT and
cannot be divulged to a third party without the expressed written consent of Exova. 
 This quotation and the services are governed by the terms and
conditions (“the Conditions”) as attached. This quotation may be accepted by signing the enclosed copy in the space provided below and returning it, for receipt by Exova within the time for acceptance given above. It will then constitute
an agreement between us (the “Contract”). Please be advised that a purchase order is acceptable for billing purposes only, and the work is governed by the attached terms and conditions. 

ACCEPTED BY 
  

					
	 /s/ R K
	  	 IntersectENT
	  	 12/13/13

	Signature	  	Company Name	  	Date


  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.